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Abstract Staphylococcal Q-hemolysin and leukocidin are bi-
component cytolysins, consisting of LukF (or Hlg1)/Hlg2 and
LukF/LukS, respectively. Here, we purified serum inhibitors of
Q-hemolysin and leukocidin from human plasma. Protein
sequencing showed that the purified inhibitors of 62, 57, 50 and
38 kDa were the vitronectin fragments with truncation(s) of the
C-terminal or both N- and C-terminal regions. The purified
vitronectin fragments specifically bound to the Hlg2 component
of Q-hemolysin and the LukS component of leukocidin to form
high-molecular-weight complexes with them, leading to inhibition
of the toxin-induced lysis of human erythrocytes and human
polymorphonuclear leukocytes, respectively. Intact vitronectin
also showed inhibitory activity to the toxins. The ability of
Q-hemolysin and leukocidin to bind vitronectin and its fragments
is a novel function of the pore-forming cytolysins.
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1. Introduction
Staphylococcus aureus is an important pathogen in wound
and soft tissue infections, and its nosocomial transmission
through asymptomatic carriers and arti¢cial implants is a seri-
ous problem. However, the pathophysiology of staphylococcal
infections is still enigmatic, partly because of the ability of the
bacterium to produce a variety of putative virulence factors
including cytolysins. Staphylococcal Q-hemolysin (Hlg) and
leukocidin (Luk) have been isolated as bi-component cytoly-
sins from the culture £uids of S. aureus [1^6], and they are
produced by most clinical isolates of the bacterium [7]. Staph-
ylococcal Hlg consists of Hlg1 and Hlg2, which cooperatively
lyse human and rabbit erythrocytes [1,5]. Staphylococcal Luk
comprises LukS and LukF, and it exhibits leukocytolytic ac-
tivity towards human and rabbit polymorphonuclear leuko-
cytes [1^4]. Previous studies by us and the other groups
showed that Hlg1 is identical with LukF, and that Hlg2 and
LukS are the determinants for the cell speci¢cities of Luk and
Hlg although these components have 72% identity in their
amino acid sequences [6,8^10].
Washed erythrocytes were used, instead of de¢brinized
blood, for selection of Hlg-producing colonies of S. aureus,
because clear zone formation by Hlg-producing S. aureus was
retarded or inhibited on the plates containing de¢brinized
blood [5]. In fact, we observed that a Hlg producer, S. aureus
Smith 5R, showed a marked delay in clear zone formation on
blood agar plates with 5% (v/v) de¢brinized blood from hu-
man or rabbit. In our preliminary experiments, human serum
inhibited Hlg activity in a dose-dependent manner, and the
inhibitory activity of human serum towards Hlg was signi¢-
cantly reduced when the serum was heated at 100‡C for 10 min
or treated with proteinase K (5 mg/ml) at 37‡C for 1 h.
Furthermore, half of the inhibitory activity was recovered in
the non-Q-globulin fraction, when human serum was frac-
tionated by ammonium sulfate precipitation. These results
suggested that proteinaceous Hlg inhibitor(s) other than
natural antibodies against Hlg are present in human serum.
In this study, we puri¢ed inhibitors of Hlg and Luk from
human plasma, and identi¢ed them as vitronectin fragments.
The puri¢ed inhibitors speci¢cally bound to the Hlg2 compo-
nent of Hlg and the LukS component of Luk, forming high-
molecular-weight complexes with these toxin components.
The ability of Hlg and Luk to bind vitronectin and its frag-
ments is a novel function of these pore-forming toxins.
2. Materials and methods
2.1. Staphylococcal Hlg and Luk
The LukF (or Hlg1), the Hlg2, and the LukS components of Hlg
and Luk were puri¢ed from the culture supernatants of S. aureus
Smith 5R strain as described previously [6].
2.2. Hemolytic assay for Hlg and leukocytolytic assay for Luk
The hemolytic assay was performed using human erythrocytes as
described previously [6]. One hundred percent hemolysis was de¢ned
as the average value of absorbance at 541 nm obtained from the
osmotically lysed erythrocytes. Luk activity towards human polymor-
phonuclear leukocytes was assayed by the dye exclusion method using
trypan blue, as described previously [11].
2.3. Assay for Hlg inhibitors
Test samples were serially two-fold diluted with 10 mM phosphate
bu¡er, pH 7.2, with 140 mM NaCl (phosphate-bu¡ered saline, PBS).
The serial dilutions were mixed with Hlg (1.2 pmol of LukF and
1.2 pmol of Hlg2), followed by incubation with 0.5% (v/v) human
erythrocytes in a total volume of 200 Wl at 37‡C for 20 min. The
mixtures were centrifuged at 1000Ug for 5 min, and the supernatants
obtained were assayed for absorbance at 541 nm. Inhibitory activity
(U/ml) of a test sample was calculated as the reciprocal of the sample
volume which inhibited 50% of the Hlg-induced hemolysis under the
conditions described above.
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2.4. Puri¢cation of Hlg inhibitors from human plasma
All puri¢cation steps were carried out at 4‡C, except for the high
performance column chromatography. Inhibitor fractions obtained
from each step were treated with 1 mM phenylmethylsulfonyl £uoride
(PMSF) unless otherwise stated. Pooled human plasma (600 ml) was
mixed with PBS (600 ml) and saturated ammonium sulfate solution
(300 ml). After stirring for 10 min, the mixture was centrifuged at
8000Ug for 30 min. The supernatant obtained (1400 ml) was mixed
with saturated ammonium sulfate solution (840 ml), and the mixture
was stirred for 30 min and centrifuged at 8000Ug for 1 h. The pre-
cipitates obtained were dissolved in PBS (200 ml) containing 1 mM
PMSF and 10 mM EDTA, and centrifuged with a Hitachi RP42 rotor
(Hitachi, Tokyo, Japan) at 120 000Ug for 3 h. A clean intermediate
layer was collected and dialyzed against 30 mM Tris-HCl bu¡er (pH
8.3) containing 50 mM NaCl, and loaded onto a DEAE-Toyopearl
650M column (diameter 35 mm, height 105 mm) previously equili-
brated with the same bu¡er. Adsorbed fractions were eluted with two
linear gradients of NaCl (50^150 mM and 150^500 mM; Fig. 1).
Adsorbed inhibitory fractions, or fractions I and II were eluted with
approximately 100 and 300 mM NaCl, respectively, and were sepa-
rately puri¢ed. Fraction I or II was mixed with the same volume of 30
mM Tris-HCl bu¡er (pH 8.3) containing 3 M ammonium sulfate, and
the mixture was loaded onto a phenyl-Toyopearl 650M column (di-
ameter 17 mm, height 50 mm). Adsorbed proteins were eluted with a
descending linear gradient of ammonium sulfate (1.5^0 M). The in-
hibitory fractions eluted with 0.2^0 M ammonium sulfate were col-
lected and dialyzed against 20 mM Tris-HCl bu¡er (pH 8.3), and
fractionated on a high performance liquid chromatograph using a
TSKgel DEAE-5PW column (diameter 7.5 mm, height 75 mm). Ad-
sorbed proteins were eluted with a linear gradient of 130^300 mM
NaCl.
2.5. Polyacrylamide gel electrophoresis (PAGE) and Western
immunoblot
Native PAGE was performed as described by Davis [12]. SDS-
PAGE under reducing conditions was performed as described by
Laemmli [13]. SDS-PAGE under non-reducing conditions was done
as described by Laemmli except that samples were pretreated with 2%
SDS at room temperature in the absence of 2-mercaptoethanol. West-
ern immunoblot was done using speci¢c antisera and horseradish
peroxidase-conjugated protein A (Sigma Chemicals, St. Louis, MO,
USA) as described previously [14]. Preparative SDS-PAGE using a
10% acrylamide disc gel (diameter 7 mm, height 40 mm) was per-
formed at 4‡C using a Bio-Rad Model 491 Mini Prep Cell (Bio-Rad
Laboratory, Hercules, CA, USA) as described by the manufacturer.
2.6. Enzyme-linked immunosorbent assay for the binding of toxins to
immobilized Hlg inhibitors
Puri¢ed inhibitors from fraction II (0.25 Wg protein in 50 Wl of PBS)
were immobilized on the wells of 96-well microplates (Nunc, Roskilde
Denmark) at 4‡C overnight. After blocking with 1% (w/v) bovine
serum albumin, serial two-fold dilutions of Hlg2, LukF or LukS (0^
0.15 Wg protein in 50 Wl) were added to the wells and incubated at
room temperature for 2 h. The wells were washed three times with
PBS containing 0.05% (w/v) Tween-20. Dilutions (50 Wl) of rabbit
antiserum against Hlg2, LukF or LukS were added and incubated
at 37‡C for 2 h. Alkaline phosphatase-conjugated goat immunoglo-
bulins against rabbit immunoglobulins (Promega Co., Madison, WI,
USA) were added to the wells, and incubated at 37‡C for 1 h. p-
Nitrophenylphosphate was used as a substrate for alkaline phospha-
tase.
2.7. Sucrose gradient centrifugation of toxin-vitronectin complexes
Puri¢ed inhibitors from fraction II were concentrated by lyophili-
zation, and rehydrated before the experiments. The inhibitors (100 Wg
protein in 50 Wl) were mixed with Hlg2 or LukS (60 Wg protein in
50 Wl), and incubated at 37‡C for 20 min. The mixture was loaded
onto a 5^20% (w/w) sucrose gradient and centrifuged using a Beck-
man SW55Ti rotor (Beckman Instruments Inc., Palo Alto, CA, USA)
at 120 000Ug at 4‡C for 15 h.
2.8. Miscellaneous
Protein was assayed according to Bradford [15], using bovine serum
albumin as a standard. Protein sequencing was done for the protein
bands blotted onto a polyvinylidene di£uoride sheet by using an Ap-
plied Biosystems Model 491 Protein Sequencer (Perkin-Elmer Applied
Biosystems, Foster City, CA, USA) [16]. Human plasma was kindly
supplied from Miyagi Red Cross Blood Center (Sendai, Japan). Hu-
man plasma vitronectin and human plasmin were from Iwaki Glass
Co. (Tokyo, Japan) and Sigma Chemicals, respectively. Anti-porcine-
vitronectin serum raised in rabbit was from LSL Co. (Tokyo, Japan).
Chemicals used were of the highest grade commercially available.
3. Results and discussion
3.1. Puri¢cation of Hlg inhibitory proteins from human plasma
and their identi¢cation as vitronectin fragments
Serum inhibitors of Hlg were puri¢ed from pooled human
plasma by the method including ammonium sulfate precipita-
tion, ultracentrifugation, and successive column chromatogra-
phy using DEAE-Toyopearl 650M, phenyl-Toyopearl 650M,
and TSKgel DEAE-5PW, as described in Section 2. As shown
in Fig. 1, Hlg inhibitors were recovered in an unadsorbed
fraction and in two adsorbed fractions (fractions I and II)
from DEAE-Toyopearl 650M column chromatography. The
adsorbed fractions I and II were separately puri¢ed by the
column chromatography with phenyl-Toyopearl 650M and
TSKgel DEAE-5PW (results not shown). SDS-PAGE under
reducing conditions showed that the puri¢ed fraction II con-
tained one major protein of 57 kDa and two minor proteins
of 50 and 38 kDa (Fig. 2A, lane 1), and that the puri¢ed
fraction I gave one major protein band corresponding to 57
kDa and three minor protein bands corresponding to 62, 50
and 38 kDa (Fig. 2A, lane 2). The protein bands were blotted
Fig. 1. An elution pro¢le of Hlg inhibitors from DEAE-Toyopearl 650M column chromatography. Percent inhibition of Hlg activity (b) and
absorbance at 280 nm (E) were assayed as described in Section 2. Dotted line indicates concentration of NaCl (mM). The bars indicate the in-
hibitory fractions combined as fractions I and II.
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onto a polyvinylidene di£uoride sheet, and their N-terminal
amino acid sequences were determined: Asp-Gln-Glu-Ser-X-
Lys-Gly-Arg-X-Thr-Glu-Gly-Phe-Asn-Val-Asp-Lys-Lys- for
the proteins of 62 and 57 kDa, Gly-Asp-Val-Phe-Thr-Met-
Pro-Glu-Asp-Glu-Tyr-X-Val-Tyr-Asp-Asp-Gly-Glu- for the
50-kDa protein, and Gly-Asn-Pro-Glu-Gln-Thr-Pro-Val-Leu-
Lys-Pro-Glu-Glu-Glu- for the 38 kDa protein (where X indi-
cates unspeci¢ed amino acid residue). A similarity search on
the DDBJ/GenBank/EMBL nucleic acid sequence database
indicated that all these proteins were vitronectin fragments:
the proteins of 57 and 62 kDa had an N-terminal amino acid
sequence identical to that of intact human vitronectin, and the
N-terminal amino acid sequences of the 50 and 38 kDa pro-
teins were identical with the internal amino acid sequences of
vitronectin which start from Gly46 and Gly89 of the molecule,
respectively. All these protein bands of fractions I and II were
immunostained with a speci¢c antiserum raised against por-
cine vitronectin (Fig. 2A, lanes 3 and 4). Thus, the Hlg inhib-
itors from human plasma were identi¢ed as vitronectin frag-
ments. Approximately 2 and 8 mg of the puri¢ed vitronectin
fragments were obtained from fractions I and II, respectively,
when 600 ml of pooled human plasma was used as the starting
material. Recovery of total inhibitory activity was approxi-
mately 5%. Speci¢c activity of the Hlg inhibitors from fraction
II was increased up to 630-fold, compared with that of the
human plasma used. Fifty percent of the Hlg-induced hemol-
ysis was inhibited by 0.37 Wg protein of the puri¢ed inhibitors
from fraction II under standard conditions.
To study whether or not each of the vitronectin fragments
has the inhibitory activity to Hlg, the puri¢ed inhibitors from
fraction II were concentrated by lyophilization, treated with
2% SDS at room temperature for 5 min, and fractionated on a
preparative SDS-PAGE. As shown in Fig. 3, the 38 kDa frag-
ment was puri¢ed to homogeneity, and it showed a dose-de-
pendent inhibitory activity to Hlg (Fig. 3). The 57 kDa frag-
ment was puri¢ed nearly to homogeneity, and it showed a
dose-dependent inhibitory activity (Fig. 3). The results also
suggested that the 50 kDa fragment had inhibitory activity
to Hlg, because fraction 58 showed a higher inhibitory activity
than fraction 52, although both fractions contained similar
amounts of the 38 kDa fragment (Fig. 3). Taken together
with the N-terminal amino acid sequence and the molecular
size of the 38 kDa fragment, an essential domain for the
inhibitory activity of vitronectin to Hlg may be located in
its central part consisting of the C-terminal half of the con-
necting region, the hemopexin 1 domain, and the N-terminal
quarter of the hemopexin 2 domain [17].
The puri¢ed Hlg inhibitors from fraction II gave immuno-
stained bands corresponding to 57, 50 and 38 kDa irrespective
of the treatment with 2-mercaptoethanol at 100‡C (results not
shown). However, the puri¢ed Hlg inhibitors gave immuno-
stained bands corresponding to 180, 150^130, and 115 kDa on
SDS-PAGE under non-reducing conditions, when they had
been lyophilized or frozen and thawed (results not shown).
The lyophilized and the frozen-and-thawed inhibitors gave
protein bands corresponding to 57, 50, and 38 kDa on
SDS-PAGE under reducing conditions (results not shown).
These results suggested that the vitronectin fragments were
not disul¢de-linked with one another in the fresh prepara-
tions, and signi¢cant portions of the vitronectin fragments
became disul¢de-linked and/or non-covalently linked with
one another through lyophilization and freezing and thawing.
However, no signi¢cant di¡erence was found between the in-
hibitory activities of the non-treated, the lyophilized, and the
frozen-and-thawed vitronectin fragments to Hlg, suggesting
that the vitronectin fragments were functionally active as
Hlg inhibitors irrespective of the molecular forms.
The other Hlg inhibitors, which were eluted in the unad-
sorbed fraction from DEAE-Toyopearl 650M column chro-
matography (Fig. 1), were also analyzed by Western immuno-
blot analyses using antisera against human immunoglobulins
and porcine vitronectin. The results showed that the unad-
sorbed fraction contained immunoglobulins but no signi¢cant
amount of vitronectin (results not shown), indicating that the
unadsorbed Hlg inhibitors were natural antibodies to Hlg.
3.2. Inhibitory activity of intact vitronectin towards Hlg
Inhibitory activity of intact vitronectin to Hlg was studied
using an authentic vitronectin preparation, which was puri¢ed
from human plasma essentially as described by Hayman et al.
[18]. The vitronectin preparation inhibited the Hlg-induced
hemolysis in a dose-dependent manner, and 5.5 Wg of the
intact vitronectin caused 50% inhibition of the Hlg activity
under standard assay conditions. Thus, intact vitronectin
had an inhibitory activity to Hlg, but it was 15-fold less active
than the puri¢ed Hlg inhibitors on protein basis. Further-
Fig. 2. SDS-PAGE and Western immunoblot for the puri¢ed Hlg inhibitors. Lanes 1 and 2: puri¢ed Hlg inhibitors (5 Wg protein) from frac-
tions II and I, respectively, were electrophoresed on a SDS-polyacrylamide gel under reducing conditions, followed by stain with Coomassie
brilliant blue R-250. Lanes 3 and 4: puri¢ed Hlg inhibitors (0.3 Wg protein) from fractions II and I, respectively, were subjected to SDS-PAGE
under reducing conditions, followed by Western immunoblot using anti-vitronectin serum. VN: vitronectin.
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more, inhibitory activity of intact vitronectin was raised to a
comparable level to that of the puri¢ed vitronectin fragments
when partially digested with human plasmin, i.e. 0.8 Wg of the
plasmin-treated vitronectin inhibited 50% of the Hlg-induced
hemolysis under the standard conditions, and SDS-PAGE for
the plasmin-treated vitronectin showed the presence of protein
bands corresponding to 62 and 38 kDa.
3.3. Speci¢c binding of the vitronectin fragments to the Hlg2
component of Q-hemolysin and the LukS component of
leukocidin
Binding of LukF and Hlg2 to human erythrocytes was as-
sayed in the presence of Hlg inhibitors. As shown in Fig. 4,
the Hlg inhibitors blocked the binding of Hlg2 to erythrocytes
as well as the Hlg-induced hemolysis in a dose-dependent
manner (Fig. 4, lanes 2, 5^7). In contrast, the Hlg inhibitors
did not a¡ect the binding of LukF to the cells irrespective of
the presence of Hlg2 (Fig. 4, lanes 2^4). These results sug-
gested that the Hlg inhibitors speci¢cally bound to Hlg2 and
inactivated the component. An enzyme-linked immunosorbent
assay using antisera against LukF and Hlg2 showed that Hlg2
bound to immobilized Hlg inhibitors in a dose-dependent
manner and showed half-maximal binding at a concentration
of approximately 0.3 Wg/ml, while LukF showed no signi¢cant
binding to the Hlg inhibitors at 30 Wg/ml under the same
conditions.
Since Hlg2 has 72% identity with the LukS component of
Luk in amino acid sequence [6,8], we studied e¡ects of the
puri¢ed vitronectin fragments on leukocidin activity. LukS
(1.6 pmol) and LukF (1.6 pmol) were incubated with or with-
out the vitronectin fragments at 37‡C for 10 min, followed by
the incubation with human polymorphonuclear leukocytes
(1U104 cells) in a total volume of 20 Wl at 37‡C for 10 min.
In the absence of the vitronectin fragments, LukS and LukF
induced 100% lysis of the leukocytes under the conditions. In
contrast, addition of the vitronectin fragments to the reaction
mixtures inhibited the leukocytolytic activity in a dose-de-
pendent manner: 10, 25 and 50 Wg of the vitronectin frag-
ments inhibited 55, 58, and 100% of the leukocidin activity,
respectively (average values from three independent experi-
ments). An enzyme-linked immunosorbent assay also showed
that LukS bound to the immobilized vitronectin fragments in
Fig. 4. E¡ect of the Hlg inhibitors on the binding of Hlg to human
erythrocytes. Hlg (0.15 Wg of LukF and 0.15 Wg of Hlg2) was mixed
with the Hlg inhibitors (2.5, 5, 10 or 15 Wg protein), and then incu-
bated with human erythrocytes (5U108 cells) in 0.4 ml of PBS at
37‡C for 20 min. A small portion of the mixtures were withdrawn
and assay for percent hemolysis. The rest of the mixtures were cen-
trifuged to collect erythrocyte membranes, and the erythrocyte mem-
branes obtained were subjected to SDS-PAGE under reducing con-
ditions, followed by Western immunoblot using a mixture of diluted
antisera against LukF and Hlg2. +: Added. 3 : Not added.
Fig. 3. Separation of the vitronectin fragments by preparative SDS-PAGE (A) and inhibitory activity of the separated vitronectin fragments to-
wards Hlg (B). A preparation of Hlg inhibitors was lyophilized and fractionated on preparative SDS-PAGE under non-reducing conditions as
described in Section 2. A: A portion of the fractions obtained were analyzed by SDS-PAGE under reducing conditions. The protein bands
were stained with Coomassie brilliant blue R-250. B: The rest of the fractions were used for assay of their inhibitory activity to Hlg after re-
moval of SDS by electrodialysis against PBS.
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Fig. 5. Sedimentation pro¢les of vitronectin-Hlg2 complexes, the vitronectin fragments, and Hlg2 in a sucrose gradient centrifugation (A), na-
tive PAGE/Western immunoblot (B), and SDS-PAGE/Western immunoblot (C and D) for the fractions from the centrifugation. A: A mixture
of the Hlg inhibitors (100 Wg) and Hlg2 (60 Wg) was incubated in TBS (100 Wl) at 37‡C for 20 min, and fractionated using a 5^20% (w/w) su-
crose gradient centrifugation, as described in Section 2. Absorbance at 280 nm was assayed for the fractions obtained from the centrifugation.
A representative sedimentation pro¢le of the vitronectin-Hlg2 complexes (b) is illustrated. Sedimentation pro¢les of the vitronectin fragments
alone (O) and Hlg2 alone (E) are also illustrated. B and C: A portion of the fractions from the centrifugation of the mixture of vitronectin
and Hlg2 was withdrawn and subjected to native PAGE (B) or SDS-PAGE under non-reducing conditions (C), followed by Western immuno-
blot using anti-vitronectin (left panels) or anti-Hlg2 serum (right panels). D: The Western immunoblot was done for the fractions from sucrose
gradient centrifugation of the vitronectin fragments alone (left panel) and Hlg2 alone (right panel).
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a dose-dependent manner, and the binding of LukS to the
inhibitors took place at a comparable level to that of Hlg2
(i.e. the concentration of LukS for half-maximal binding was
approximately 0.75 Wg/ml).
Complex formation between the vitronectin fragments and
Hlg2 was analyzed by sucrose gradient centrifugation (Fig.
5A), followed by native PAGE/Western immunoblot (Fig.
5B) and SDS-PAGE/Western immunoblot (Fig. 5C) using
antisera against vitronectin and Hlg2. When a mixture of
the vitronectin fragments and Hlg2 was incubated and centri-
fuged in a 5^20% (w/w) sucrose gradient, a broad peak com-
prising the vitronectin fragments and Hlg2 sedimented faster
than those of the vitronectin fragments alone and Hlg2 alone
(Fig. 5A,D). Native PAGE/Western immunoblot showed that
the vitronectin fragments and Hlg2 co-sedimented on the su-
crose gradient and moved together in the native gel (Fig. 5B),
indicating complex formation between the vitronectin frag-
ments and Hlg2. SDS-PAGE/Western immunoblot con¢rmed
the co-sedimentation of the vitronectin fragments and Hlg2 in
the sucrose gradient centrifugation (Fig. 5C). However, Hlg2
did not migrate together with the vitronectin fragments in the
SDS-polyacrylamide gel, suggesting that the complexes of the
vitronectin fragments with Hlg2 were dissociated in the pres-
ence of 2% SDS (Fig. 5C). Experiments using sucrose density
gradient centrifugation and Western immunoblot under the
same conditions showed that the vitronectin fragments also
formed complexes with the LukS component of Luk (results
not shown).
In the present study, we puri¢ed serum inhibitors of Hlg
and Luk from human plasma and identi¢ed them as vitronec-
tin fragments. Since vitronectin exists primarily as an intact 75
kDa molecule and a nicked molecule consisting of an N-ter-
minal 65 kDa fragment and a C-terminal 10 kDa fragment in
human plasma [18^21], the puri¢ed inhibitors of Hlg and Luk
may have derived proteolytically from the intact and the
nicked molecules during puri¢cation, probably by the action
of serum protease(s) such as plasmin. In fact, intact and
nicked vitronectin molecules were detected by Western immu-
noblot for fraction I of the DEAE-Toyopearl 650M column
chromatography (results not shown), and the limited digestion
of intact vitronectin by human plasmin produced inhibitory
fragments with molecular masses of 62, 42, and 38 kDa (re-
sults not shown). Furthermore, vitronectin is one of the major
serum proteins, and its concentration in human serum has
been estimated to be 300^500 Wg/ml [19,20] (i.e. s 10-fold
higher concentrations than that causing 50% inhibition of
Hlg under standard conditions). Taken together, vitronectin
and its fragments are considered to be the major serum in-
hibitors of Hlg and Luk.
Vitronectin is present in the extracellular matrix of many
tissues as well as in plasma. So, it should be noted that limited
proteolysis of vitronectin may occur in the extracellular ma-
trix of normal and lesional human tissues, because vitronectin
fragments of 61^63, 58, 50, 42, and 35 kDa were detected by
Western immunoblot analyses for freshly excised samples of
human normal skin [22] and for retina extracts from patients
with proliferative diabetic retinopathy [23]. The vitronectin
fragments might play some physiological and/or pathological
roles in normal and lesional tissues. Since vitronectin is con-
sidered to regulate proteolytic enzyme cascades including the
complement, coagulation and ¢brinolysis systems [17], it
would act as an ambivalent factor for hosts in the loci of
staphylococcal infections. (i) Vitronectin and its fragments
capture Hlg2 and LukS in the extracellular matrix of ¢bro-
blasts and tissue macrophages, leading to integrin-mediated
endocytosis and degradation of the toxins by the cells [24].
(ii) However, the resultant lower level of vitronectin would
cause tissue injuries by an excess level of terminal complex
of complement and hyperproduction of plasmin. (iii) Vitro-
nectin has been shown to be a binding molecule for S. aureus
[25]. Binding of Hlg and Luk to vitronectin in the extracellular
matrix would cause spreading of tissue-bound staphylococci.
Thus, not only cytolytic activity but also vitronectin binding
activity of Hlg and Luk are the putative pathophysiological
functions of the staphylococcal bi-component toxins.
Acknowledgements: This work was supported in part by a Grant-in-
Aid for Scienti¢c Research from the Ministry of Education, Science,
Sports and Culture of Japan. The authors are very grateful to Miyagi
Red Cross Blood Center for supplying human plasma.
References
[1] Tomita, T. and Kamio, Y. (1997) Biosci. Biotechnol. Biochem.
61, 565^572.
[2] Gladstone, G.P. and Van Heyningen, W.E. (1957) Br. J. Exp.
Pathol. 38, 123^137.
[3] Woodin, A.M. (1960) Biochem. J. 75, 158^165.
[4] Noda, M., Hirayama, T., Kato, I. and Matsuda, F. (1980) Bio-
chim. Biophys. Acta 633, 33^44.
[5] Guyonnet, F. and Plommet, M. (1970) Ann. Inst. Pasteur 118,
19^33.
[6] Rahman, A., Izaki, K., Kato, I. and Kamio, Y. (1991) Biochem.
Biophys. Res. Commun. 181, 138^144.
[7] Prevost, G., Couppie, P., Prevost, S., Gayet, S., Petiau, P.,
Cribier, B., Monteil, H. and Piemont, Y. (1995) J. Med. Micro-
biol. 42, 237^245.
[8] Kamio, Y., Rahman, A., Nariya, N., Ozawa, T. and Izaki, K.
(1993) FEBS Lett. 321, 15^18.
[9] Supersac, G., Prevost, G. and Piemont, Y. (1993) Infect. Immun.
61, 580^587.
[10] Coony, J., Kienle, Z., Foster, T.J. and O’Toole, P.W. (1993)
Infect. Immun. 61, 768^771.
[11] Nariya, H., Nishiyama, A. and Kamio, Y. (1997) FEBS Lett.
415, 96^100.
[12] Davis, B.J. (1964) Ann. NY Acad. Sci. 121, 404^427.
[13] Laemmli, U.K. (1970) Nature 277, 680^685.
[14] Sugawara, N., Tomita, T. and Kamio, Y. (1997) FEBS Lett. 410,
333^337.
[15] Bradford, M.M. (1976) Anal. Biochem. 72, 248^254.
[16] Matsudaira, P. (1987) J. Biol. Chem. 262, 10035^10038.
[17] Preissner, K. (1991) Annu. Rev. Cell Biol. 7, 275^310.
[18] Hayman, E.G., Pierschbacher, M.D., Oehgren, Y. and Ruoslahti,
E. (1983) Proc. Natl. Acad. Sci. USA 80, 4003^4007.
[19] Podack, E.R. and Mueller-Eberhard, H.J. (1979) J. Biol. Chem.
254, 9908^9914.
[20] Preissner, K.T. and Wassmuth, R. (1985) Biochem. J. 231, 349^
355.
[21] Yatohgo, T., Izumi, M., Kashiwagi, H. and Hayashi, M. (1988)
Cell Struct. Funct. 13, 281^292.
[22] Hiltner, H., Dahlbaeck, K., Pepys, M.B. and Breathnach, S.M.
(1991) J. Invest. Dermatol. 96, 747^753.
[23] Casaroli Marano, R.P., Preissner, K.T. and Vilaro, S. (1995)
Exp. Eye Res. 60, 5^17.
[24] Panetti, T.S. and McKeown-Longo, P.J. (1993) J. Biol. Chem.
268, 11988^11993.
[25] Fuquay, J.I., Loo, D.T. and Barnes, D.W. (1986) Infect. Immun.
52, 714^717.
FEBS 22813 28-10-99
H. Katsumi et al./FEBS Letters 460 (1999) 451^456456
